Lipid-based Particles Research Articles

How do lipid-based drug delivery systems affect the pharmacokinetic and tissue distribution of amiodarone? A comparative study of liposomes, solid lipid nanoparticles, and nanoemulsions.

Lipid-based drug delivery systems (DDS) can improve the pharmacokinetic (PK) parameters of some drugs. Especially those with a high volume of distribution (Vd) leading to off-target accumulation and toxicity. Amiodarone as an anti-arrhythmic agent induces hypothyroidism and liver disorders limiting its clinical indication. In the present study, amiodarone PK parameters and biodistribution after IV administration of four nano-formulations to rats were compared. The formulations were liposomes, solid lipid nanoparticles (SLN), PEGylated SLN (PEG-SLN), and nanoemulsions (NE). All formulations were optimized. The nanoparticles were spherical with a diameter of 100-200 nm and sustained in vitro drug release in buffer pH 7.4. The best-fitted model for the plasma concentration-time profile was two-compartmental. In vivo studies indicated the most changes in PKs induced after liposome, SLN, and NE administration, respectively. The area under the curve (AUC) and maximum plasma concentration (Cmax) of liposomes, SLN, and NE were 22.5, 2.6, 2.46 times, and 916, 58, and 26 times higher than that of amiodarone solution, respectively (P-value<0.05). The heart-to-liver ratio of amiodarone was higher for nano-formulations compared to drug solution except for liposomes. Lipid-based particles can improve the PK parameters of amiodarone and its distribution in different tissues.

A short review on the applicability and use of cubosomes as nanocarriers.

Cubosomes are nanostructured lipid-based particles that have gained significant attention in the field of drug delivery and nanomedicine. These unique structures consist of a three-dimensional cubic lattice formed by the self-assembly of lipid molecules. The lipids used to construct cubosomes are typically nonionic surfactants, such as monoolein, which possess both hydrophilic and hydrophobic regions, allowing them to form stable, water-dispersible nanoparticles. One of the key advantages of cubosomes is their ability to encapsulate and deliver hydrophobic as well as hydrophilic drugs. The hydrophobic regions of the lipid bilayers provide an ideal environment for incorporating lipophilic drugs, while the hydrophilic regions can encapsulate water-soluble drugs. This versatility makes cubosomes suitable for delivering a wide range of therapeutic agents, including small molecules, proteins, peptides, and nucleic acids. The unique structure of cubosomes also offers stability and controlled release benefits. The lipid bilayers provide a protective barrier, shielding the encapsulated drugs from degradation and improving their stability. Moreover, the cubic lattice arrangement enables the modulation of drug release kinetics by varying the lipid composition and surface modifications. This allows for the development of sustained or triggered drug release systems, enhancing therapeutic efficacy and reducing side effects. Furthermore, cubosomes can be easily modified with targeting ligands or surface modifications to achieve site-specific drug delivery, enhancing therapeutic selectivity and reducing off-target effects. In conclusion, cubosomes offer a versatile and promising platform for the delivery of therapeutic agents. In this manuscript, we will highlight some of these applications.

FOLFIRINOX-loaded immunoliposome-like particles for localized pancreatic cancer treatment

FOLFIRINOX therapy, a combination of oxaliplatin, 5-fluorouracil, irinotecan, and leucovorin, is one of the most applied treatment schemes for pancreatic adenocarcinoma. However, because this form of treatment causes significant side effects, it has become important to reduce the dose of the drug administered to the patients and target the drug to the tumor tissue. This study presents the liposomal type of this therapy scheme to demonstrate its applicability to localized chemotherapy strategies. Briefly, lipid-based liposome-like particles have been synthesized and physically, chemically, and thermally characterized. Following the decoration of the liposome-like particles with anti-Mucin-4, a malignancy marker for pancreatic adenocarcinoma, the encapsulation efficiency of the FOLFIRINOX components and release profile of the FOLFIRINOX-loaded liposome-like particles have been analyzed using the high-pressure liquid chromatography. Cytotoxicity analyses and cellular encapsulation studies of Mucin-4-targeted liposome-like particles were performed in HPAF-II (ascites-derived cell, Mucin-4(+)) and PANC-I (tumor-derived cell, Mucin-4(−)) cells. The results have shown that Mucin-4-targeted liposome-like particles enter HPAF-II cells more selectively than PANC-I cells. Besides, after the FOLFIRINOX application, a significant difference was observed between the viability of HPAF-II and PANC-I cells at 100-fold dilution. In genotoxicity and apoptosis analysis, it was found that drug-loaded liposome-like particles caused DNA damage in cancer cells with the increase in concentration. The study suggests that Mucin-4-targeted liposome-like particles can provide superior patient welfare and a promising treatment model for pancreatic adenocarcinoma and can be used in localized chemotherapy applications due to their long-term stability, nanoscale size, and target-driven nature.

Extracellular Vesicles Released from Cancer Cells Promote Tumorigenesis by Inducing Epithelial to Mesenchymal Transition via β-Catenin Signaling

Lung cancer is the leading cause of cancer-related deaths globally, in part due to a lack of early diagnostic tools and effective pharmacological interventions. Extracellular vesicles (EVs) are lipid-based membrane-bound particles released from all living cells in both physiological and pathological states. To understand the effects of lung-cancer-derived EVs on healthy cells, we isolated and characterized EVs derived from A549 lung adenocarcinoma cells and transferred them to healthy human bronchial epithelial cells (16HBe14o). We found that A549-derived EVs carry oncogenic proteins involved in the pathway of epithelial to mesenchymal transition (EMT) that are regulated by β-catenin. The exposure of 16HBe14o cells to A549-derived EVs resulted in a significant increase in cell proliferation, migration, and invasion via upregulating EMT markers such as E-Cadherin, Snail, and Vimentin and cell adhesion molecules such as CEACAM-5, ICAM-1, and VCAM-1, with concomitant downregulation of EpCAM. Our study suggests a role for cancer-cell-derived EVs to induce tumorigenesis in adjacent healthy cells by promoting EMT via β-catenin signaling.

Biomaterial-enabled 3D cell culture technologies for extracellular vesicle manufacturing.

Extracellular vesicles (EVs) are lipid-based particles naturally released from cells and recognized as promising drug delivery vehicles for improving therapeutic outcomes. Efficient manufacturing of therapeutic EVs have been challenging for their clinical translations. Three-dimensional (3D) cell cultures enabled by biomaterial scaffolds have been used as a platform for improving EV manufacturing compared to conventional methods such as isolation from bodily fluids and standard Petri-dish cell culture. Recent studies on 3D culture derived EV production prove it to enhance the EV yield, functional cargos, and therapeutic efficacies. However, there are still challenges with scaling up 3D cell culture production platforms for industrial use. Hence, there is a high demand for designing, optimizing, and implementing large scale EV manufacturing platforms derived from 3D cell cultures. We will first review the current advances of biomaterial-enabled 3D cell cultures in EV manufacturing, followed by the effect of these 3D cell culture platforms on the EV yield, the EV quality, and therapeutic efficacies. Lastly, we will discuss the key challenges and potential for implementing biomaterial-enabled 3D culture in EV manufacturing for large scale processes in the industrial use.

Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA.

Vectorized small interfering RNAs (siRNAs) are widely used to induce gene silencing. Among the delivery systems used, lipid-based particles are the most effective. Our objective was the development of novel lipid-polymer hybrid nanoparticles, from lipoplexes (complexes of cationic lipid and siRNAs), and poly (lactic-co-glycolic acid) (PLGA), using a simple modified nanoprecipitation method. Due to their morphology, we called these hybrid nanoparticles Spheroplexes. We elucidated their structure using several physico-chemical techniques and showed that they are composed of a hydrophobic PLGA matrix, surrounded by a lipid envelope adopting a lamellar structure, in which the siRNA is complexed, and they retain surface characteristics identical to the starting nanoparticles, i.e. lipoplexes siRNA. We analyzed the composition of the particle population and determined the final percentage of spheroplexes within this population, 80 to 85% depending on the preparation conditions, using fluorescent markers and the ability of flow cytometry to detect nanometric particles (approximately 200nm). Finally, we showed that spheroplexes are very stable particles and more efficient than siRNA lipoplexes for the delivery of siRNA to cultured cells. We administered spheroplexes contain siRNAs targeting TNF-α to mice with ulcerative colitis induced by dextran sulfate and our results indicate a disease regression effect with a response probably mediated by their uptake by macrophages / monocytes at the level of lamina propria of the colon. The efficacy of decreased level of TNF-α in vivo seemed to be an association of spheroplexes polymer-lipid composition and the specific siRNA. These results demonstrate that spheroplexes are a promising hybrid nanoparticle for the oral delivery of siRNA to the colon.

Solvent-Free Fabrication of Biphasic Lipid-Based Microparticles with Tunable Structure

Lipid-based biphasic microparticles are generally produced by long and complex techniques based on double emulsions. In this study, spray congealing was used as a solvent-free fabrication method with improved processability to transform water-in-oil non-aqueous emulsions into spherical solid lipid-based particles with a biphasic structure (b-MPs). Emulsions were prepared by melt emulsification using different compositions of lipids (Dynasan®118 and Compritol®888 ATO), surfactants (Cetylstearyl alcohol and Span®60) and hydrophilic carriers (PEGs, Gelucire®48/16 and Poloxamer 188). First, pseudo-ternary phase diagrams were constructed to identify the area corresponding to each emulsion type (coarse emulsion or microemulsion). The hydrophobicity of the lipid mostly affected the interfacial tension, and thus the microstructure of the emulsion. Emulsions were then processed by spray congealing and the obtained b-MPs were characterized in terms of thermal and chemical properties (by DSC and FT-IR), external and internal morphology (by SEM, CLSM and Raman mapping). Solid free-flowing spherical particles (main size range 200–355 µm) with different architectures were successfully produced: microemulsions led to the formation of particles with a homogeneous internal structure, while coarse emulsions generated “multicores-shell” particles consisting of variable size hydrophilic cores evenly distributed within the crystalline lipid phase. Depending on their composition and structure, b-MPs could achieve various release profiles, representing a more versatile system than microparticles based on a single lipid phase. The formulation and technological strategy proposed, provides a feasible and cost-effective way of fabricating b-MPs with tunable internal structure and release behavior.

A review on multivesicular liposomes for pharmaceutical applications: preparation, characterization, and translational challenges.

Multivesicular liposomes (MVLs) are non-concentric, lipid-based micron-sized spherical particles. The usage of MVL for sustained drug delivery has seen progression over the last decade due to successful clinical and commercial applications. It provides attractive characteristics, such as high encapsulation efficiency, variety of sizes, structural stability, and different choices for the route of administration. Drug molecules are encapsulated in internal aqueous compartments of MVL, separated by lipid bilayer septa to form polyhedral structures. The integrity of these entrapped small molecules, peptides, or proteins is maintained throughout the therapy, thus providing sustained drug release on non-vascular administration. Despite the frequent use of unilamellar liposomes, characterization of MVLs is critical due to different puzzling problems, such as real-time size evaluation, initial burst, and in vivo performance. Moreover, available regulatory guidelines on liposomal drug product development are insufficient to assure ample in vitro-in vivo behavior of MVL. This review hereby highlights the innovations pertaining to development and manufacturing procedures, drug release mechanisms, and characterization techniques. The review also summarizes the applications, challenges, and future perspectives for successfully translating the research concept to a clinically accepted delivery system. Despite the intricacies involved in the development of MVL, establishing steadfast characterization techniques and regulatory paths could pave the way to its extensive clinical use.

Research Progress of Physiological Activity and Preparations of Anthocyanins

With the improvement of living standards, people gradually develop a scientific way of life. As a natural antioxidant, anthocyanin has the functions of anti-oxidation, anti-aging, scavenging free radicals, anti-inflammation, bacteriostasis, preventing obesity, cardiovascular protection, lowering blood sugar, improving eyesight, improving cognitive ability, preventing senile dementia, preventing cancer and other active effects. Because of its high nutritional value, safety, non-toxicity, rich resources and a variety of physiological activities, it has great potential in food, makeup, medicine and other applications. However, anthocyanin is unstable under the conditions of temperature, light, pH, metal particles, which limits its biological activity and application. The stability of anthocyanins can be improved by adding co-pigments, phenolic compounds, phenolic acids, flavonoids, amino acids and peptides, proteins, natural sweeteners and so on. But, anthocyanins have been in the process of degradation, and these methods have some limitations in the process of application. In recent years, embedding with suitable materials has shown great potential in the stabilization of food active ingredients and the improvement of bioavailability. Common methods include microcapsules, nanoparticles, lipid-based particles such as emulsions and liposomes, and nano/microgels and so on. Though, the stability time of anthocyanins is shorter than other products in the market, and can’t fully meet the market demand, so it’s necessary to develop new methods to increase the stability of anthocyanins. This article outlines the methods of extracting and separating anthocyanins, and summarizes the research status of anthocyanins' physiological activities and their preparations, and provides references for in-depth research on anthocyanins in the fields of medicine and food.

New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes

The main objective of the MACIVIVA European consortium was to develop new Good Manufacturing Practice pilot lines for manufacturing thermostable vaccines with stabilized antigens on influenza virosomes as enveloped virus-like particles. The HIV-1 gp41-derived antigens anchored in the virosome membrane, along with the adjuvant 3M-052 (TLR7/8 agonist) on the same particle, served as a candidate vaccine for the proof of concept for establishing manufacturing processes, which can be directly applied or adapted to other virosomal vaccines or lipid-based particles. Heat spray-dried powders suitable for nasal or oral delivery, and freeze-dried sublingual tablets were successfully developed as solid dosage forms for mucosal vaccination. The antigenic properties of vaccinal antigens with key gp41 epitopes were maintained, preserving the original immunogenicity of the starting liquid form, and also when solid forms were exposed to high temperature (40 °C) for up to 3 months, with minimal antigen and adjuvant content variation. Virosomes reconstituted from the powder forms remained as free particles with similar size, virosome uptake by antigen-presenting cells in vitro was comparable to virosomes from the liquid form, and the presence of excipients specific to each solid form did not prevent virosome transport to the draining lymph nodes of immunized mice. Virosome integrity was also preserved during exposure to <−15 °C, mimicking accidental freezing conditions. These “ready to use and all-in-one” thermostable needle-free virosomal HIV-1 mucosal vaccines offer the advantage of simplified logistics with a lower dependence on the cold chain during shipments and distribution.

O/W emulsions stabilised by solid lipid particles: Understanding how the particles’ Pickering functionality can be retained post their dehydration and subsequent rehydration

Pickering particles have been extensively shown to hold an immense potential as emulsion stabilisers. Lipid-based particles in particular, are increasingly studied as edible Pickering structures. The aim of this work was to investigate whether specific formulation parameters that are key for the fabrication of lipid particles with a Pickering functionality can also impact upon the ability of these structures to withstand drying and subsequent rehydration events, without loss to their original capacity to provide stable o/w emulsions. The formulation parameters studied here included the type of the lipid source, type and concentration of the surface active species and type and concentration of cryoprotectants used. Freeze-drying was used as the process for the dehydration of the fabricated lipid particles, while two methods for the subsequent rehydration of these structures were tested. It is demonstrated that lipid particles fabricated using sodium caseinate during the melt-emulsification step can maintain their original Pickering functionality even following lyophilisation; i.e., once reconstituted, they provide stable o/w emulsions with the same droplet sizes as those produced by their precursors (lipid particles that haven’t undergone the freezing and desiccation stages). In contrast, a typical small molecular weight surfactant (Tween 80) does not exhibit the same functionality as the protein, and lipid particle agglomeration following drying and reconstitution was unavoidable, even in the presence of traditional drying aids (cryoprotectants) in the formulation. Parameters relating to the drying and rehydration stages (drying kinetics, final moisture content and storage conditions) were also studied, but their impact upon the Pickering functionality of the reconstituted lipid particles was deemed secondary to the effects brought upon by changes to formulation elements.Overall, the present work advances the current limited understanding on formulation approaches that enable the conservation of the Pickering functionality of the lipid particles following their drying and rehydration, in particular offering insight into the contribution of the specific emulsifier employed during particle fabrication.

Nano/microencapsulation of anthocyanins; a systematic review and meta-analysis

Anthocyanins, a kind of phenolic compounds are present in plant kingdom. They exhibit biological activities such as anti-inflammatory and anti-cancer properties as well as imparting colors to various plants. The objective of this review is to provide a systematic evaluation of the evidence and a meta-analysis of published researches on the nano/microencapsulation of anthocyanins. A comprehensive literature search was conducted for articles published in 2016 to 2019 on PubMed, Web of Sciences and Scopus databases. Overall 45 eligible articles (51 cases; some authors studied 2 or more encapsulation methods) with appropriate data were included in the statistical analysis. In the current work, based on the technique and equipment applied for the formulation of micro/nanoencapsulation systems, the anthocyanin-loaded nano/microcarriers were classified into five main classes: (a) spray dried particles (spray-drying); (b) freeze-dried particles (freeze-drying); (c) lipid-based particles (emulsification and liposomal encapsulation); (d) electrospun fibers and electrosprayed particles (electrohydrodynamic encapsulation); and (e) nano/micro-gels (gelation). Based on the results from the meta-analysis, the studied technique for encapsulation of anthocyanins can be ordered as: spray-drying (33.33%), freeze-drying (27.08%), gelation (20.83%), lipid-based particles (14.58%) and electrohydrodynamic processes (4.17%). In addition, carbohydrates such as maltodextrin (19.56%) and gums (15.22%) have been the most frequently used biopolymers for encapsulation of anthocyanins in the selected studies.

Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.

Despite efforts made to develop efficient preventive strategies, infections with influenza A viruses (IAV) continue to cause serious clinical and economic problems. Current licensed human vaccines are mainly inactivated whole virus particles or split-virion administered via the parenteral route. These vaccines provide incomplete protection against IAV in high-risk groups and are poorly/not effective against the constant antigenic drift/shift occurring in circulating strains. Advances in mucosal vaccinology and in the understanding of the protective anti-influenza immune mechanisms suggest that intranasal immunization is a promising strategy to fight against IAV. To date, human mucosal anti-influenza vaccines consist of live attenuated strains administered intranasally, which elicit higher local humoral and cellular immune responses than conventional parenteral vaccines. However, because of inconsistent protective efficacy and safety concerns regarding the use of live viral strains, new vaccine candidates are urgently needed. To prime and induce potent and long-lived protective immune responses, mucosal vaccine formulations need to ensure the immunoavailability and the immunostimulating capacity of the vaccine antigen(s) at the mucosal surfaces, while being minimally reactogenic/toxic. The purpose of this review is to compile innovative delivery/adjuvant systems tested for intranasal administration of inactivated influenza vaccines, including micro/nanosized particulate carriers such as lipid-based particles, virus-like particles and polymers associated or not with immunopotentiatory molecules including microorganism-derived toxins, Toll-like receptor ligands and cytokines. The capacity of these vaccines to trigger specific mucosal and systemic humoral and cellular responses against IAV and their (cross)-protective potential are considered.

Extracellular Vesicles: Opportunities and Challenges for the Treatment of Renal Diseases.

Extracellular vesicles (EVs) are lipid-based membrane-bound particles secreted by virtually all types of cells under both physiological and pathological conditions. Given their unique biological and pharmacological properties, EVs have spurred a renewed interest in their utility for therapeutics. Herein, efforts are made to give a comprehensive overview on the recent advances of EV-based therapy in renal diseases. The fact that EVs are implicated in various renal diseases provides us with new therapeutic modalities by eliminating these pathogenic entities. Strategies that target EVs to inhibit their production, release, and uptake will be discussed. Further, EVs-derived predominantly from stem cells can stimulate tissue repair and ameliorate renal injury via transferring proteins and nucleic acids to injured cells. Such EVs can be exploited as agents in renal regenerative medicine. Finally, we will focus on the specific application of EVs as a novel drug delivery system and highlight the challenges of EVs-based therapies for renal diseases.

Probing cell-nanoparticle (cubosome) interactions at the endothelial interface: do tissue dimension and flow matter?

In the research field of nanostructured systems for biomedical applications, increasing attention has been paid to using biomimetic, dynamic cellular models to adequately predict their bio-nano behaviours. This work specifically evaluates the biointeractions of nanostructured lipid-based particles (cubosomes) with human vascular cells from the aspects of tissue dimension (conventional 2D well plate versus 3D dynamic tubular vasculature) and shear flow effect (static, venous and arterial flow-mimicking conditions). A glass capillary-hosted, 3D tubular endothelial construct was coupled with circulating luminal fluid flow to simulate the human vascular systems. In the absence of fluid flow, the degree of cell-cubosome association was not significantly different between the 2D planar and the 3D tubular systems. Under flow conditions simulating venous (0.8 dynes per cm2) and arterial (10 dynes per cm2) shear stresses, the cell-cubosome association notably declined by 50% and 98%, respectively. This highlights the significance of shear-guided biointeractions of non-targeted nanoparticles in the circulation. Across all 2D and 3D cellular models with and without flow, cubosomes had little effect on the cell-cell contact based on the unchanged immunoexpression of the endothelial-specific intercellular junction marker PECAM-1. Interestingly, there were dissimilar nanoparticle distribution patterns between the 2D planar (showing discrete punctate staining) and the 3D tubular endothelium (with a more diffused, patchy fashion). Taken together, these findings highlight the importance of tissue dimension and shear flow in governing the magnitude and feature of cell-nanoparticle interactions.

Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Vaccination is the process of administering immunogenic formulations in order to induce or harness antigen (Ag)-specific antibody and T cell responses in order to protect against infections. Important successes have been obtained in protecting individuals against many deleterious pathological situations after parenteral vaccination. However, one of the major limitations of the current vaccination strategies is the administration route that may not be optimal for the induction of immunity at the site of pathogen entry, i.e., mucosal surfaces. It is now well documented that immune responses along the genital, respiratory, or gastrointestinal tracts have to be elicited locally to ensure efficient trafficking of effector and memory B and T cells to mucosal tissues. Moreover, needle-free mucosal delivery of vaccines is advantageous in terms of safety, compliance, and ease of administration. However, the quest for mucosal vaccines is challenging due to (1) the fact that Ag sampling has to be performed across the epithelium through a relatively limited number of portals of entry; (2) the deleterious acidic and proteolytic environment of the mucosae that affect the stability, integrity, and retention time of the applied Ags; and (3) the tolerogenic environment of mucosae, which requires the addition of adjuvants to elicit efficient effector immune responses. Until now, only few mucosally applicable vaccine formulations have been developed and successfully tested. In animal models and clinical trials, the use of lipidic structures such as liposomes, virosomes, immune stimulating complexes, gas-filled microbubbles and emulsions has proven efficient for the mucosal delivery of associated Ags and the induction of local and systemic immune reponses. Such particles are suitable for mucosal delivery because they protect the associated payload from degradation and deliver concentrated amounts of Ags via specialized sampling cells (microfold cells) within the mucosal epithelium to underlying antigen-presenting cells. The review aims at summarizing recent development in the field of mucosal vaccination using lipid-based particles. The modularity ensured by tailoring the lipidic design and content of particles, and their known safety as already established in humans, make the continuing appraisal of these vaccine candidates a promising development in the field of targeted mucosal vaccination.

Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies.

Lipid-based particles are used worldwide in clinical trials as carriers of hydrophobic paclitaxel (PTXL) for cancer chemotherapy, albeit with little improvement over the standard-of-care. Improving efficacy requires an understanding of intramembrane interactions between PTXL and lipids to enhance PTXL solubilization and suppress PTXL phase separation into crystals. We studied the solubility of PTXL in cationic liposomes (CLs) composed of positively charged 2,3-dioleyloxypropyltrimethylammonium chloride (DOTAP) and neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) as a function of PTXL membrane content and its relation to efficacy. Time-dependent kinetic phase diagrams were generated from observations of PTXL crystal formation by differential-interference-contrast microscopy. Furthermore, a new synchrotron small-angle x-ray scattering in situ methodology applied to DOTAP/DOPC/PTXL membranes condensed with DNA enabled us to detect the incorporation and time-dependent depletion of PTXL from membranes by measurements of variations in the membrane interlayer and DNA interaxial spacings. Our results revealed three regimes with distinct time scales for PTXL membrane solubility: hours for >3mol% PTXL (low), days for≈3mol% PTXL (moderate), and ≥20 days for<3mol% PTXL (long-term). Cell viability experiments on human cancer cell lines using CLPTXL nanoparticles (NPs) in the distinct CLPTXL solubility regimes reveal an unexpected dependence of efficacy on PTXL content in NPs. Remarkably, formulations with lower PTXL content and thus higher stability show higher efficacy than those formulated at the membrane solubility limit of ≈3mol% PTXL (which has been the focus of most previous physicochemical studies and clinical trials of PTXL-loaded CLs). Furthermore, an additional high-efficacy regime is seen on occasion for liposome compositions with PTXL ≥9mol% applied to cells at short time scales (hours) after formation. At longer time scales (days), CLPTXL NPs with ≥3mol% PTXL lose efficacy while formulations with 1-2mol% PTXL maintain high efficacy. Our findings underscore the importance of understanding the relationship of the kinetic phase behavior and physicochemical properties of CLPTXL NPs to efficacy.

Topographic analysis by atomic force microscopy of proteoliposomes matrix vesicle mimetics harboring TNAP and AnxA5

Atomic force microscopy (AFM) is one of the most commonly used scanning probe microscopy techniques for nanoscale imaging and characterization of lipid-based particles. However, obtaining images of such particles using AFM is still a challenge. The present study extends the capabilities of AFM to the characterization of proteoliposomes, a special class of liposomes composed of lipids and proteins, mimicking matrix vesicles (MVs) involved in the biomineralization process. To this end, proteoliposomes were synthesized, composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phospho-l-serine (DPPS), with inserted tissue-nonspecific alkaline phosphatase (TNAP) and/or annexin V (AnxA5), both characteristic proteins of osteoblast-derived MVs. We then aimed to study how TNAP and AnxA5 insertion affects the proteoliposomes' membrane properties and, in turn, interactions with type II collagen, thus mimicking early MV activity during biomineralization. AFM images of these proteoliposomes, acquired in dynamic mode, revealed the presence of surface protrusions with distinct viscoelasticity, thus suggesting that the presence of the proteins induced local changes in membrane fluidity. Surface protrusions were measurable in TNAP-proteoliposomes but barely detectable in AnxA5-proteoliposomes. More complex surface structures were observed for proteoliposomes harboring both TNAP and AnxA5 concomitantly, resulting in a lower affinity for type II collagen fibers compared to proteoliposomes harboring AnxA5 alone. The present study achieved the topographic analysis of lipid vesicles by direct visualization of structural changes, resulting from protein incorporation, without the need for fluorescent probes.

Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresis.

Several vaccine adjuvants comprise complex nano- or micro-particle formulations, such as oil-in-water emulsions. In order to characterize interactions and compatibility of oil-in-water emulsion adjuvants with protein antigens in vaccines, effective protein characterization methods that can accommodate potential interference from high concentrations of lipid-based particles are needed. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a standard protein characterization technique which is affected by the presence of adjuvants such as oil-in-water emulsions. In this article, we investigate variations in SDS-PAGE methods that result in a reduction of adjuvant-induced staining artifacts. We have investigated whether the SDS method or the adjuvant composition were the reason for these artifacts and succeeded in reducing the artifacts with a modified sample preparation and different staining procedures. The best results were obtained by using gold staining or silver staining instead of a Coomassie Blue staining procedure. Moreover, the replacement of the dilution buffer (20% SDS to disrupt emulsion) by alternative detergents such as Tween® 80 and Triton® X-100 removed adjuvant-induced streaking artifacts at the top of the gel. These methods may be useful for improving characterization approaches of antigen-adjuvant mixtures by SDS-PAGE.

Targeting and modulating infarct macrophages with hemin formulated in designed lipid-based particles improves cardiac remodeling and function

Uncontrolled activation of pro-inflammatory macrophages after myocardial infarction (MI) accelerates adverse left ventricular (LV) remodeling and dysfunction. Hemin, an iron-containing porphyrin, activates heme oxygenase-1 (HO-1), an enzyme with anti-inflammatory and cytoprotective properties. We sought to determine the effects of hemin formulated in a macrophage-targeted lipid-based carrier (denoted HA-LP) on LV remodeling and function after MI.Hemin encapsulation efficiency was ~100% at therapeutic dose levels. In vitro, hemin/HA-LP abolished TNF-α secretion from macrophages, whereas the same doses of free hemin and drug free HA-LP had no effect. Hemin/HA-LP polarized peritoneal and splenic macrophages toward M2 anti-inflammatory phenotype. We next induced MI in mice and allocated them to IV treatment with hemin/HA-LP (10mg/kg), drug free HA-LP, free hemin (10mg/kg) or saline, one day after MI. Active in vivo targeting to infarct macrophages was confirmed with HA-LP doped with PE-rhodamine. LV remodeling and function were assessed by echocardiography before, 7, and 30days after treatment. Significantly, hemin/HA-LP effectively and specifically targets infarct macrophages, switches infarct macrophages toward M2 anti-inflammatory phenotype, improves angiogenesis, reduces scar expansion and improves infarct-related regional function.In conclusion, macrophage-targeted lipid-based drug carriers with hemin switch macrophages into an anti-inflammatory phenotype, and improve infarct healing and repair. Our approach presents a novel strategy to modulate inflammation and improve infarct repair.